<DOC>
	<DOCNO>NCT00080054</DOCNO>
	<brief_summary>The purpose study find safety add investigational drug motexafin gadolinium standard course chemotherapy temozolomide patient malignant glioma . Secondly , study determine many patient respond treatment .</brief_summary>
	<brief_title>A Study Motexafin Gadolinium Temozolomide Treatment Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>At least 18 year old Histologically confirm diagnosis malignant glioma require systemic antineoplastic treatment . Malignant glioma define follow : Glioblastoma multiforme ( GBM ) ; Anaplastic astrocytoma ( AA ) ; Anaplastic oligodendroglioma ; Anaplastic mix glioma ; Glioma otherwise specify ( except lowgrade glioma ) ECOG performance status score 0 , 1 , 2 Each patient must sign studyspecific inform consent form Laboratory value : Absolute neutrophil count &lt; 2000/µL Platelet count &lt; 100,000/µL AST ALT &gt; 2 x upper limit normal ( ULN ) Alkaline phosphatase &gt; 5 x ULN Bilirubin &gt; 2 x ULN Creatinine &gt; 2.0 mg/µL Plan use additional cancer therapy ( e.g. , systemic , radiation , surgery ) study period Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Malignant Glioma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>AA</keyword>
	<keyword>Anaplastic oligodendroglioma</keyword>
	<keyword>Anaplastic mixed glioma</keyword>
	<keyword>Brain tumor</keyword>
	<keyword>Brain neoplasm</keyword>
	<keyword>Glioma</keyword>
</DOC>